Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.
P/E ratio for Jubilant Pharmova Limited (JUBLPHARMA.NS)
P/E ratio as of 2023: 118.13
According to Jubilant Pharmova Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 118.13. At the end of 2022 the company had a P/E ratio of -72.78.
P/E ratio history for Jubilant Pharmova Limited from 2003 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 118.13 |
| 2022 | -72.78 |
| 2021 | 14.93 |
| 2020 | 12.98 |
| 2019 | 4.42 |
| 2018 | 18.58 |
| 2017 | 20.97 |
| 2016 | 22.11 |
| 2015 | 15.37 |
| 2014 | -42.12 |
| 2013 | 23.22 |
| 2012 | 18.36 |
| 2011 | 218.45 |
| 2010 | 11.43 |
| 2009 | 12.81 |
| 2008 | 5.37 |
| 2007 | 13.03 |
| 2006 | 18.16 |
| 2005 | 29.91 |
| 2004 | 23.03 |
| 2003 | 29.97 |